CV Sciences ventures into immunity with new supplements range
The CBD products company strategically moves into an emerging space amid COVID-19 immunity demands
30 Jul 2020 --- Cannabidiol (CBD) products company CV Sciences is strategically expanding into the category of condition specific dietary supplements with the launch of CV Acute. The product is touted as supporting the immune system and respiratory health and is the first of several to be launched under the company’s immunity line. This space is seeing rapid expansion due to COVID-19-related health concerns. Traditionally active in CBD, CV Sciences’ move toward immunity is expected to open new markets and sales channels, including major e-commerce retailers not currently accessible by CBD-related products.
CV Acute is a clinically researched, wide-spectrum, proprietary plant-based product, which integrates a time tested Traditional Chinese Medicine (TCM) herbal formula with proprietary modern analytical chemistry and extraction techniques. It is supported by global medical authorities and an array of scientific studies that demonstrate overall immune system defense to everyday challenges with enhanced support for respiratory health, the company affirms.
“The launch of CV Acute represents a strategic category expansion and a natural evolution of CV Sciences’ positioning as a leading health and wellness company,” notes Joseph Dowling, CEO of CV Sciences.
The launch of CV Acute represents a strategic category expansion for CV Sciences.“CV Acute is considered a valuable botanical formula to maintain immune and respiratory health at times when protection is needed the most, including the uncertain times of the 2020/2021 flu season. This is particularly important as many retailers have not been able to offer CBD products, which have also demonstrated immune system support.”
Clinically backed?
A World Health Organization (WHO) report has cited the formula’s ability to be an effective therapy for respiratory and immune system challenges that can be safely combined with conventional and pharmaceutical treatments. Furthermore, a March 2020 study published in the International Journal of Biological Sciences highlighted in vitro evidence demonstrating that the formula had a preventive effect on SARS-COV2, the virus that causes COVID-19. While this data is preliminary and should be interpreted conservatively, the strong safety profile of CV Acute indicates that it is a prudent addition to an integrated approach to respiratory and immune challenges.
Michael D. Lewis, MD, MPH, Colonel (Retired), US Army and CV Sciences Medical Advisor explains that he was assigned to establish the Department of Defense Global Emerging Infections Surveillance Program in Southeast Asia in the early 2000’s, helping manage both the SARS and avian influenza outbreaks for the US military. “There I observed the tremendous value in combining traditional herbs with modern diagnosis and treatment,” he says.
“TCM herbs have powerful anti-viral and anti-inflammatory activity without side-effects [often] associated with drugs. The herbs in CV Acute have been shown to be safe and effective alone or when added to modern medical treatment of viral and bacterial infections,” Lewis notes.
“We considered adding CBD to the formula, however our goal is to make CV Acute broadly available to consumers through all retail channels at an affordable price so they can have easy access to the immune and respiratory health benefits this formula has demonstrated to provide. We view PlusCBD as a companion product to CV Acute because PlusCBD provides maintenance for the immune and endocannabinoid systems, while CV Acute delivers high intensity immune support when needed,” concludes Dowling.
CV Acute will be available at select retailers US-wide and through major e-commerce retailers next month.
Edited by Kristiana Lalou
